source
- Sarepta CEO Sees Path to Stronger DMD Trials Amid 2025 Elevidys SetbacksSarepta Therapeutics’ newly appointed chief executive Michael Severino, after a 90‑day assessment period, outlined a plan to restore the company’s leadership in the Duchenne muscular dystrophy mark…
- Moderna pauses norovirus vaccine trial after missing interim analysisModerna announced it will not enroll a new cohort in the phase 3 trial of its mRNA-1403 norovirus vaccine. The decision follows a July interim analysis that showed the vaccine missed its predefine…